Duration of Clopidogrel Therapy After Drug-Eluting Stent (DES-LATE)

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 5000 participants.

Also called NCT01186146

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 5,000 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01186146
Other papers using this trial's data
  • Optimal duration of dual antiplatelet therapy after drug-eluting stent implantation: a randomized, controlled trial Circulation, 2014-01-21 DOI, PubMed 24097439

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
South Korea (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01186146. Randomized; no masking; primary purpose treatment. Start 2010-08 (registry gives no type); primary completion 2012-12 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Duration of Clopidogrel Therapy After Drug-Eluting Stent (DES-LATE)
Acronym
DES-LATE
Intervention (Drug)
Aspirin monotherapy
Intervention (Drug)
Aspirin,Clopidogrel
Lead sponsor
Seung-Jung Park (class: other)
Collaborator
CardioVascular Research Foundation, Korea (class: other)

Record details

Record id
cardio:ct-nct01186146
Content hash
62b95edab79058cdab212c719063b4eef0ee7b840d063119a7600f95cd57b1e3